Skeletal muscle mitochondrial uncoupling in a murine cancer cachexia model

International Journal of Oncology

Volumn 43, Issue 3, 2013, Pages 886-894

  Aria Tzika, A ^a   Fontes Oliveira, Cibely Cristine ^b   Shestov, Alexander A ^c   Constantinou, Caterina ^a   Psychogios, Nikolaos ^a   Righi, Valeria ^a   Mintzopoulos, Dionyssios ^a   Busquets, Silvia ^b   Lopez Soriano, Francisco J ^b   Milot, Sylvain ^e   Lepine, Francois ^e   Mindrinos, Michael N ^d   Rahme, Laurence G ^a   Argiles, Josep M ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e INRS INSTITUT ARMAND FRAPPIER   (Canada)

Author keywords

Adenosine triphosphate; Cancer cachexia; Gas chromatography mass spectrometry; Mitochondria; Nuclear magnetic resonance spectroscopy; Peroxisome proliferator activated receptor co activator 1 ; Skeletal muscle; Tricarboxylic acid; Uncoupling protein 3

Indexed keywords

ADENOSINE TRIPHOSPHATE; TRICARBOXYLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CACHEXIA; CHRONIC DISEASE; CITRIC ACID CYCLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENOME; IN VIVO STUDY; LEWIS CARCINOMA; MALE; MASS FRAGMENTOGRAPHY; MOUSE; MUSCLE CELL; NONHUMAN; OXIDATIVE PHOSPHORYLATION UNCOUPLING; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; REGULATOR GENE; SKELETAL MUSCLE; TRANSMISSION ELECTRON MICROSCOPY;

ADENOSINE TRIPHOSPHATE; ANIMALS; CACHEXIA; CITRIC ACID CYCLE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; MITOCHONDRIA; MUSCLE, SKELETAL; NEOPLASMS;

EID: 84880644479     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1998     Document Type: Article

References (111)

1. Tisdale MJ: Cachexia in cancer patients. Nat Rev Cancer 2: 862-871, 2002.
2. McCarthy DO: Rethinking nutritional support for persons with cancer cachexia. Biol Res Nurs 5: 3-17, 2003.
3. al-Majid S and McCarthy DO: Cancer-induced fatigue and skeletal muscle wasting: the role of exercise. Biol Res Nurs 2: 186-197, 2001.
4. Evans WJ, Morley JE, Argilés J, et al: Cachexia: a new definition. Clin Nutr 27: 793-799, 2008.
5. Windsor JA and Hill GL: Risk factors for postoperative pneumonia. The importance of protein depletion. Ann Surg 208: 209-214, 1988.
6. Mitch WE and Goldberg AL: Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med 335: 1897-1905, 1996.
7. Cogswell PC, Guttridge DC, Funkhouser WK and Baldwin AS Jr: Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene 19: 1123-1131, 2000.
8. Guttridge DC, Mayo MW, Madrid LV, Wang CY and Baldwin AS Jr: NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 289: 2363-2366, 2000.
9. Hasselgren PO and Fischer JE: Muscle cachexia: current concepts of intracellular mechanisms and molecular regulation. Ann Surg 233: 9-17, 2001.
10. Chen S, Guttridge DC, You Z, et al: Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription. J Cell Biol 152: 87-96, 2001.
11. You Z, Saims D, Chen S, et al: Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis. J Cell Biol 157: 429-440, 2002.
12. Hasselgren PO, Wray C and Mammen J: Molecular regulation of muscle cachexia: it may be more than the proteasome. Biochem Biophys Res Commun 290: 1-10, 2002.
13. Argilés JM, Busquets S and López-Soriano FJ: The role of uncoupling proteins in pathophysiological states. Biochem Biophys Res Commun 293: 1145-1152, 2002.
14. Ardenkjaer-Larsen JH, Fridlund B, Gram A, et al: Increase in signal-to-noise ratio of >10,000 times in liquid-state NMR. Proc Natl Acad Sci USA 100: 10158-10163, 2003.
15. Gutstein HB: Mechanisms underlying cancer-induced symptoms. Drugs Today (Barc) 39: 815-822, 2003.
16. Acharyya S, Ladner KJ, Nelsen LL, et al: Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 114: 370-378, 2004.
17. Guttridge DC: Signaling pathways weigh in on decisions to make or break skeletal muscle. Curr Opin Clin Nutr Metab Care 7: 443-450, 2004.
18. Lecker SH, Jagoe RT, Gilbert A, et al: Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 18: 39-51, 2004.
19. Sandri M, Sandri C, Gilbert A, et al: Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117: 399-412, 2004.
20. Acharyya S, Butchbach ME, Sahenk Z, et al: Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell 8: 421-432, 2005.
21. Argilés JM, Busquets S, Felipe A and López-Soriano FJ: Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. Int J Biochem Cell Biol 37: 1084-1104, 2005.
22. Argilés JM, Busquets S and López-Soriano FJ: The pivotal role of cytokines in muscle wasting during cancer. Int J Biochem Cell Biol 37: 2036-2046, 2005.
23. Li YP, Chen Y, John J, et al: TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J 19: 362-370, 2005.
24. Skipworth RJ, Stewart GD, Ross JA, Guttridge DC and Fearon KC: The molecular mechanisms of skeletal muscle wasting: implications for therapy. Surgeon 4: 273-283, 2006.
25. Sandri M, Lin J, Handschin C, et al: PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci USA 103: 16260-16265, 2006.
26. Busquets S, Deans C, Figueras M, et al: Apoptosis is present in skeletal muscle of cachectic gastro-intestinal cancer patients. Clin Nutr 26: 614-618, 2007.
27. Melstrom LG, Melstrom KA Jr, Ding XZ and Adrian TE: Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia. Histol Histopathol 22: 805-814, 2007.
28. Acharyya S and Guttridge DC: Cancer cachexia signaling pathways continue to emerge yet much still points to the proteasome. Clin Cancer Res 13: 1356-1361, 2007.
29. Zhao J, Brault JJ, Schild A, et al: FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab 6: 472-483, 2007.
30. Argilés JM, López-Soriano FJ and Busquets S: Apoptosis signalling is essential and precedes protein degradation in wasting skeletal muscle during catabolic conditions. Int J Biochem Cell Biol 40: 1674-1678, 2008.
31. Arany Z: PGC-1 coactivators and skeletal muscle adaptations in health and disease. Curr Opin Genet Dev 18: 426-434, 2008.
32. Sandri M: Signaling in muscle atrophy and hypertrophy. Physiology (Bethesda) 23: 160-170, 2008.
33. Tisdale MJ: Mechanisms of cancer cachexia. Physiol Rev 89: 381-410, 2009.
34. Popiela T, Lucchi R and Giongo F: Methylprednisolone as palliative therapy for female terminal cancer patients. The Methylprednisolone Female Preterminal Cancer Study Group. Eur J Cancer Clin Oncol 25: 1823-1829, 1989.
35. Kardinal CG, Loprinzi CL, Schaid DJ, et al: A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 65: 2657-2662, 1990.
36. Loprinzi CL, Schaid DJ, Dose AM, Burnham NL and Jensen MD: Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 11: 152-154, 1993.
37. Argilés JM, Almendro V, Busquets S and López-Soriano FJ: The pharmacological treatment of cachexia. Curr Drug Targets 5: 265-277, 2004.
38. Busquets S, Figueras MT, Fuster G, et al: Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res 64: 6725-6731, 2004.
39. Neary NM, Small CJ, Wren AM, et al: Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89: 2832-2836, 2004.
40. Smith HJ, Wyke SM and Tisdale MJ: Mechanism of the attenuation of proteolysis-inducing factor stimulated protein degradation in muscle by beta-hydroxy-beta-methylbutyrate. Cancer Res 64: 8731-8735, 2004.
41. Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T and Goggin PM: Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 54: 540-545, 2005.
42. Argilés JM, López-Soriano FJ and Busquets S: Emerging drugs for cancer cachexia. Expert Opin Emerg Drugs 12: 555-570, 2007.
43. Fuster G, Busquets S, Almendro V, López-Soriano FJ and Argilés JM: Antiproteolytic effects of plasma from hibernating bears: a new approach for muscle wasting therapy? Clin Nutr 26: 658-661, 2007.
44. Moore-Carrasco R, Busquets S, Almendro V, Palanki M, López-Soriano FJ and Argilés JM: The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia. Int J Oncol 30: 1239-1245, 2007.
45. Argilés JM, Figueras M, Ametller E, et al: Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells. Muscle Nerve 37: 190-195, 2008.
46. Fong LY, Jiang Y, Riley M, et al: Prevention of upper aerodigestive tract cancer in zinc-deficient rodents: inefficacy of genetic or pharmacological disruption of COX-2. Int J Cancer 122: 978-989, 2008.
47. Mantovani G and Madeddu C: Cyclooxygenase-2 inhibitors and antioxidants in the treatment of cachexia. Curr Opin Support Palliat Care 2: 275-281, 2008.
48. Alamdari N, O'Neal P and Hasselgren PO: Curcumin and muscle wasting: a new role for an old drug? Nutrition 25: 125-129, 2009.
49. Argilés JM, López-Soriano FJ and Busquets S: Therapeutic potential of interleukin-15: a myokine involved in muscle wasting and adiposity. Drug Discov Today 14: 208-213, 2009.
50. Beijer S, Hupperets PS, van den Borne BE, et al: Effect of adenosine 5'-triphosphate infusions on the nutritional status and survival of preterminal cancer patients. Anticancer Drugs 20: 625-633, 2009.
51. Lagirand-Cantaloube J, Cornille K, Csibi A, Batonnet-Pichon S, Leibovitch MP and Leibovitch SA: Inhibition of atrogin-1/MAFbx mediated MyoD proteolysis prevents skeletal muscle atrophy in vivo. PloS One 4: e4973, 2009.
52. Madeddu C and Mantovani G: An update on promising agents for the treatment of cancer cachexia. Curr Opin Support Palliat Care 3: 258-262, 2009.
53. Mantovani G, Macciò A, Madeddu C, et al: Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J Mol Med (Berl) 88: 85-92, 2010.
54. Mantovani G and Madeddu C: Cancer cachexia: medical management. Support Care Cancer 18: 1-9, 2010.
55. Murphy KT and Lynch GS: Update on emerging drugs for cancer cachexia. Expert Opin Emerg Drugs 14: 619-632, 2009.
56. Noé JE: L-glutamine use in the treatment and prevention of mucositis and cachexia: a naturopathic perspective. Integr Cancer Ther 8: 409-415, 2009.
57. Russell ST, Siren PM, Siren MJ and Tisdale MJ: Attenuation of skeletal muscle atrophy in cancer cachexia by D-myo-inositol 1,2,6-triphosphate. Cancer Chemother Pharmacol 64: 517-527, 2009.
58. Siddiqui RA, Hassan S, Harvey KA, et al: Attenuation of proteolysis and muscle wasting by curcumin c3 complex in MAC16 colon tumour-bearing mice. Br J Nutr 102: 967-975, 2009.
59. Taylor LA, Pletschen L, Arends J, Unger C and Massing U: Marine phospholipids - a promising new dietary approach to tumor-associated weight loss. Support Care Cancer 18: 159-170, 2010.
60. van Norren K, Kegler D, Argiles JM, et al: Dietary supplementation with a specific combination of high protein, leucine, and fish oil improves muscle function and daily activity in tumour-bearing cachectic mice. Br J Cancer 100: 713-722, 2009.
61. Weyermann P, Dallmann R, Magyar J, et al: Orally available selective melanocortin-4 receptor antagonists stimulate food intake and reduce cancer-induced cachexia in mice. PloS One 4: e4774, 2009.
62. Padfield KE, Astrakas LG, Zhang Q, et al: Burn injury causes mitochondrial dysfunction in skeletal muscle. Proc Natl Acad Sci USA 102: 5368-5373, 2005.
63. Astrakas LG, Goljer I, Yasuhara S, et al: Proton NMR spectroscopy shows lipids accumulate in skeletal muscle in response to burn trauma-induced apoptosis. FASEB J 19: 1431-1440, 2005.
64. Padfield KE, Zhang Q, Gopalan S, et al: Local and distant burn injury alter immuno-inflammatory gene expression in skeletal muscle. J Trauma 61: 280-292, 2006.
65. Zhang Q, Cao H, Astrakas LG, et al: Uncoupling protein 3 expression and intramyocellular lipid accumulation by NMR following local burn trauma. Int J Mol Med 18: 1223-1229, 2006.
66. Khan N, Mupparaju SP, Mintzopoulos D, et al: Burn trauma in skeletal muscle results in oxidative stress as assessed by in vivo electron paramegnetic resonance. Mol Med Report 1: 813-819, 2008.
67. Tzika AA, Astrakas LG, Cao H, et al: Murine intramyocellular lipids quantified by NMR act as metabolic biomarkers in burn trauma. Int J Mol Med 21: 825-832, 2008.
68. Tzika AA, Mintzopoulos D, Padfield K, et al: Reduced rate of adenosine triphosphate synthesis by in vivo 31P nuclear magnetic resonance spectroscopy and downregulation of PGC-1β in distal skeletal muscle following burn. Int J Mol Med 21: 201-208, 2008.
69. Righi V, Andronesi O, Mintzopoulos D and Tzika AA: Molecular characterization and quantification using state of the art solid-state adiabatic TOBSY NMR in burn trauma. Int J Mol Med 24: 749-757, 2009.
70. Tzika AA, Mintzopoulos D, Mindrinos M, Zhang J, Rahme LG and Tompkins RG: Microarray analysis suggests that burn injury results in mitochondrial dysfunction in human skeletal muscle. Int J Mol Med 24: 387-392, 2009.
71. Constantinou C, Fontes de Oliveira CC, Mintzopoulos D, et al: Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia. Int J Mol Med 27: 15-24, 2011.
72. Bennani-Baiti N and Walsh D: Animal models of the cancer anorexia-cachexia syndrome. Support Care Cancer 19: 1451-1463, 2011.
73. Tanaka Y, Eda H, Tanaka T, et al: Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. Cancer Res 50: 2290-2295, 1990.
74. Diffee GM, Kalfas K, Al-Majid S and McCarthy DO: Altered expression of skeletal muscle myosin isoforms in cancer cachexia. Am J Physiol Cell Physiol 283: C1376-C1382, 2002.
75. Gorselink M, Vaessen SF, van der Flier LG, et al: Mass-dependent decline of skeletal muscle function in cancer cachexia. Muscle Nerve 33: 691-693, 2006.
76. Bibby MC, Double JA, Ali SA, Fearon KC, Brennan RA and Tisdale MJ: Characterization of a transplantable adenocarcinoma of the mouse colon producing cachexia in recipient animals. J Natl Cancer Inst 78: 539-546, 1987.
77. Bing C, Brown M, King P, Collins P, Tisdale MJ and Williams G: Increased gene expression of brown fat uncoupling protein (UCP)1 and skeletal muscle UCP2 and UCP3 in MAC16-induced cancer cachexia. Cancer Res 60: 2405-2410, 2000.
78. Collins P, Bing C, McCulloch P and Williams G: Muscle UCP-3 mRNA levels are elevated in weight loss associated with gastrointestinal adenocarcinoma in humans. Br J Cancer 86: 372-375, 2002.
79. Ackerman JJ, Grove TH, Wong GG, Gadian DG and Radda GK: Mapping of metabolites in whole animals by 31P NMR using surface coils. Nature 283: 167-170, 1980.
80. Hitzig BM, Prichard JW, Kantor HL, et al: NMR spectroscopy as an investigative technique in physiology. FASEB J 1: 22-31, 1987.
81. 13C NMR multiplet data: concepts and simulations with a two-compartment neuronal-glial model. Neurochem Res 37: 2388-2401, 2012.
82. 31P NMR assessment of mitochondrial energy coupling in skeletal muscle of awake fed and fasted rats. Relationship with uncoupling protein 3 expression. J Biol Chem 275: 39279-39286, 2000.
83. Befroy DE, Falk Petersen K, Rothman DL and Shulman GI: Assessment of in vivo mitochondrial metabolism by magnetic resonance spectroscopy. Methods Enzymol 457: 373-393, 2009.
84. Cobas JC, Bernstein MA, Martín-Pastor M and Tahoces PG: A new general-purpose fully automatic baseline-correction procedure for 1D and 2D NMR data. J Magn Reson 183: 145-151, 2006.
85. Forsen S and Hoffman RA: Study of moderately rapid chemical exchange reactions by means of nuclear magnetic double resonance. J Chem Phys 39: 2892-2901, 1963.
86. Leimer KR, Rice RH and Gehrke CW: Complete mass spectra of N-trifluoroacetyl-n-butyl esters of amino acids. J Chromatogr 141: 121-144, 1977.
87. Cline GW, Vidal-Puig AJ, Dufour S, Cadman KS, Lowell BB and Shulman GI: In vivo effects of uncoupling protein-3 gene disruption on mitochondrial energy metabolism. J Biol Chem 276: 20240-20244, 2001.
88. Busquets S, Almendro V, Barreiro E, Figueras M, Argilés JM and López-Soriano FJ: Activation of UCPs gene expression in skeletal muscle can be independent on both circulating fatty acids and food intake. Involvement of ROS in a model of mouse cancer cachexia. FEBS Lett 579: 717-722, 2005.
89. Sanchís D, Busquets S, Alvarez B, Ricquier D, López-Soriano FJ and Argilés JM: Skeletal muscle UCP2 and UCP3 gene expression in a rat cancer cachexia model. FEBS Lett 436: 415-418, 1998.
90. Busquets S, Sanchís D, Alvarez B, Ricquier D, López-Soriano FJ and Argilés JM: In the rat, tumor necrosis factor alpha administration results in an increase in both UCP2 and UCP3 mRNAs in skeletal muscle: a possible mechanism for cytokine-induced thermogenesis? FEBS Lett 440: 348-350, 1998.
91. Alger JR and Shulman RG: NMR studies of enzymatic rates in vitro and in vivo by magnetization transfer. Q Rev Biophys 17: 83-124, 1984.
92. Sako EY, Kingsley-Hickman PB, From AH, Foker JE and Ugurbil K: ATP synthesis kinetics and mitochondrial function in the postischemic myocardium as studied by 31P NMR. J Biol Chem 263: 10600-10607, 1988.
93. Kingsley-Hickman PB, Sako EY, Uǧurbil K, From AH and Foker JE: 31P NMR measurement of mitochondrial uncoupling in isolated rat hearts. J Biol Chem 265: 1545-1550, 1990.
94. 31P NMR. Proc Natl Acad Sci USA 97: 6880-6884, 2000.
95. Fuster G, Busquets S, Ametller E, et al: Are peroxisome proliferator-activated receptors involved in skeletal muscle wasting during experimental cancer cachexia? Role of beta2-adrenergic agonists. Cancer Res 67: 6512-6519, 2007.
96. Roche TE, Baker JC, Yan X, et al: Distinct regulatory properties of pyruvate dehydrogenase kinase and phosphatase isoforms. Prog Nucleic Acid Res Mol Biol 70: 33-75, 2001.
97. St-Pierre J, Lin J, Krauss S, et al: Bioenergetic analysis of peroxisome proliferator-activated receptor gamma coactivators 1alpha and 1beta (PGC-1alpha and PGC-1beta) in muscle cells. J Biol Chem 278: 26597-26603, 2003.
98. Uldry M, Yang W, St-Pierre J, Lin J, Seale P and Spiegelman BM: Complementary action of the PGC-1 coactivators in mitochondrial biogenesis and brown fat differentiation. Cell Metab 3: 333-341, 2006.
99. Giordano A, Calvani M, Petillo O, Carteni M, Melone MR and Peluso G: Skeletal muscle metabolism in physiology and in cancer disease. J Cell Biochem 90: 170-186, 2003.
100. Navratil M, Terman A and Arriaga EA: Giant mitochondria do not fuse and exchange their contents with normal mitochondria. Exp Cell Res 314: 164-172, 2008.
101. Shum AM, Mahendradatta T, Taylor RJ, et al: Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting. Aging (Albany NY) 4: 133-143, 2012.
102. van Royen M, Carbó N, Busquets S, et al: DNA fragmentation occurs in skeletal muscle during tumor growth: A link with cancer cachexia? Biochem Biophys Res Commun 270: 533-537, 2000.
103. DeJong CH, Busquets S, Moses AG, et al: Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia. Oncol Rep 14: 257-263, 2005.
104. Barreiro E, de la Puente B, Busquets S, López-Soriano FJ, Gea J and Argilés JM: Both oxidative and nitrosative stress are associated with muscle wasting in tumour-bearing rats. FEBS Lett 579: 1646-1652, 2005.
105. Boveris A and Chance B: The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. Biochem J 134: 707-716, 1973.
106. Turrens JF and Boveris A: Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. Biochem J 191: 421-427, 1980.
107. Turrens JF, Freeman BA, Levitt JG and Crapo JD: The effect of hyperoxia on superoxide production by lung submitochondrial particles. Arch Biochem Biophys 217: 401-410, 1982.
108. Bandy B and Davison AJ: Mitochondrial mutations may increase oxidative stress: implications for carcinogenesis and aging? Free Radic Biol Med 8: 523-539, 1990.
109. Kwong KK, Belliveau JW, Chesler DA, et al: Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc Natl Acad Sci 89: 5675-5679, 1992.
110. Esposito LA, Melov S, Panov A, Cottrell BA and Wallace DC: Mitochondrial disease in mouse results in increased oxidative stress. Proc Natl Acad Sci USA 96: 4820-4825, 1999.
111. Imam SZ, Karahalil B, Hogue BA, Souza-Pinto NC and Bohr VA: Mitochondrial and nuclear DNA-repair capacity of various brain regions in mouse is altered in an age-dependent manner. Neurobiol Aging 27: 1129-1136, 2006.